Article | August 16, 2022

Gene Therapies For Better Kidney Treatments With Purespring Therapeutics

Source: Cytiva

According to the Centers for Disease Control and Prevention, 15 percent of U.S. adults – 37 million people – are living with chronic kidney disease, while global prevalence is estimated to exceed 840 million patients. Despite a clear need for therapies, kidney conditions have proven difficult to treat, often burdening patients with invasive options such as dialysis and transplant.

Richard Francis, CEO of Purespring Therapeutics, a gene therapy company focused on pioneering more accessible, less burdensome treatment options, has spent decades in the biopharmaceutical space trying to commercialize sea-change treatments for patients who need them. In a recent episode of The Business of Biotech, Francis explored the importance of pursuing new treatments for kidney conditions, as well as why he believes Purespring is poised for long-range commercial success.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online